Jiangsu Recbio Technology Co., Ltd. Class H (HK:2179) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jiangsu Recbio Technology has launched a phase III clinical trial in China for its novel shingles vaccine, REC610, targeting individuals aged 40 and above. This trial aims to evaluate the vaccine’s efficacy, safety, and immunogenicity, with a significant demand for domestic alternatives to the currently available vaccine. REC610 has shown promising results in earlier trials, highlighting its potential to be a strong contender in the shingles vaccine market.
For further insights into HK:2179 stock, check out TipRanks’ Stock Analysis page.